Hostname: page-component-8448b6f56d-t5pn6 Total loading time: 0 Render date: 2024-04-19T23:53:53.563Z Has data issue: false hasContentIssue false
  • English
  • Français

Association between behavioral and psychological symptoms and psychotropic drug use among old people with cognitive impairment living in geriatric care settings

Published online by Cambridge University Press:  20 June 2013

Maria Gustafsson ,
Per-Olof Sandman ,
Stig Karlsson ,
Yngve Gustafson  and
Hugo Lövheim
Maria Gustafsson*
Affiliation:
Department of Pharmacology and Clinical Neurosciences, Division of Clinical Pharmacology and Department of Community Medicine and Rehabilitation, Division of Geriatric Medicine, Umeå University, Umeå, Sweden
Per-Olof Sandman
Affiliation:
Department of Neurobiology, Care Sciences and Society, Division of Nursing, Karolinska Institutet, Stockholm, Sweden
Stig Karlsson
Affiliation:
Department of Nursing, Umeå University, Umeå, Sweden
Yngve Gustafson
Affiliation:
Department of Community Medicine and Rehabilitation, Division of Geriatric Medicine, Umeå University, Umeå, Sweden
Hugo Lövheim
Affiliation:
Department of Community Medicine and Rehabilitation, Division of Geriatric Medicine, Umeå University, Umeå, Sweden
*
Correspondence should be addressed to: Maria Gustafsson, MSc Pharm, Department of Pharmacology and Clinical Neurosciences, Umeå University, Umeå SE-901 85, Sweden. Phone: +46-90-785-35-62; Fax: +46-90-12-04-30. Email: maria.gustafsson@pharm.umu.se.
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Behavioral and psychological symptoms are common among cognitively impaired individuals and psychotropic drugs are widely used for their treatment. The aim of this study was to describe the prevalence and associated factors of psychotropic and anti-dementia drug use among old people with cognitive impairment living in geriatric care settings.

Methods:

The study comprised 2,019 cognitively impaired people living in geriatric care units in the county of Västerbotten, Sweden. Data concerning psychotropic and anti-dementia drug use, function in activities of daily living, cognitive function, and prevalence of behavioral and psychological symptoms were collected, using the Multi-Dimensional Dementia Assessment Scale.

Results:

Of the study population, 1,442 individuals (71%) were prescribed at least one psychotropic drug (antidepressants (49%), anxiolytics, hypnotics, and sedatives (36%), antipsychotics (25%)). Furthermore, 363 individuals (18%) received anti-dementia drugs. Associations between various behavioral and psychological symptoms were found for all psychotropic drug classes and anti-dementia drugs. Verbally disruptive/attention-seeking behavior was associated with all psychotropic drugs. Use of antipsychotics was associated with several behavioral and psychological symptoms, including aggressive behavior.

Conclusion:

The associations between behavioral and psychological symptoms and psychotropic drug use found in this study indicate that these drugs are prescribed to treat behavioral and psychological symptoms among cognitively impaired individuals despite limited evidence of their efficacy. Given the significant risk of adverse effects among old people with cognitive impairment, it is important to ensure that any medication used is both appropriate and safe.

Keywords

psychotropic drugsdementiaBPSDpsychotropic prescribingaggressioncognitive impairment
Type
Research Article
Information
International Psychogeriatrics , Volume 25 , Issue 9 , September 2013 , pp. 1415 - 1423
Copyright
Copyright © International Psychogeriatric Association 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adolfsson, R., Gottfries, C. G., Nyström, L. and Winblad, B. (1981). Prevalence of dementia disorders in institutionalized Swedish old people. The workload imposed by caring for these patients. Acta Psychiatrica Scandinavica, 63, 225–244.CrossRefGoogle Scholar
Ashton, H. (2005). The diagnosis and management of benzodiazepine dependence. Current Opinion in Psychiatry, 18, 249–255.CrossRefGoogle ScholarPubMed
Ballard, C. G., Waite, J. and Birks, J. (2006). Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews, CD003476 doi:10.1002/14651858.CD003476.pub2.Google ScholarPubMed
Ballard, C.et al. (2005). Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ, 330, 874. doi:10.1136/bmj.38369.459988.8F.CrossRefGoogle ScholarPubMed
Banerjee, S.et al. (2011). Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet, 378, 403–411. doi:10.1016/S0140-6736(11)60830-1.CrossRefGoogle ScholarPubMed
Cancelli, I., Beltrame, M., Gigli, G. L. and Valente, M. (2009). Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurological Sciences, 30, 87–92. doi:10.1007/s10072-009-0033-y.CrossRefGoogle ScholarPubMed
Cerejeira, J., Lagarto, L. and Mukaetova-Ladinska, E. B. (2012). Behavioral and psychological symptoms of dementia. Frontiers in Neurology, 3, s.73. doi:10.3389/fneur.2012.00073.CrossRefGoogle ScholarPubMed
Chiu, M.-J., Chen, T.-F., Yip, P.-K., Hua, M.-S. and Tang, L.-Y. (2006). Behavioral and psychologic symptoms in different types of dementia. Journal of the Formosan Medical Association, 105, 556–562.CrossRefGoogle ScholarPubMed
Gauthier, S.et al. (2010). Management of behavioral problems in Alzheimer's disease. International Psychogeriatrics, 22, 346–372. doi:10.1017/S1041610209991505.CrossRefGoogle ScholarPubMed
Glass, J., Lanctôt, K. L., Herrmann, N., Sproule, B. A. and Busto, U. E. (2005). Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ, 331, 1169. doi:10.1136/bmj.38623.768588.47.CrossRefGoogle ScholarPubMed
Gustafsson, M., Karlsson, S. and Lövheim, H. (2013). Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units. BMC Pharmacology & Toxicology, 14, s.10.CrossRefGoogle ScholarPubMed
Henry, G., Williamson, D. and Tampi, R. R. (2011). Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. American Journal of Alzheimer's Disease and Other Dementias, 26, 169–183. doi:10.1177/1533317511402051.CrossRefGoogle ScholarPubMed
Lanctôt, K. L., Herrmann, N., van Reekum, R., Eryavec, G. and Naranjo, C. A. (2002). Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. International Journal of Geriatric Psychiatry, 17, 531–541. doi:10.1002/gps.636.CrossRefGoogle ScholarPubMed
Lövheim, H., Sandman, P.-O., Kallin, K., Karlsson, S. and Gustafson, Y. (2006). Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care. International Psychogeriatrics, 18, 713–726. doi:10.1017/S1041610206003930.CrossRefGoogle ScholarPubMed
Lövheim, H., Sandman, P.-O., Karlsson, S. and Gustafson, Y. (2008). Behavioral and psychological symptoms of dementia in relation to level of cognitive impairment. International Psychogeriatrics, 20, 777–789. doi:10.1017/S1041610208006777.CrossRefGoogle ScholarPubMed
Medical Products Agency. (2008). Läkemedelsverkets behandlingsrekommendationer: Läkemedelsbehandling och bemötande vid Beteendemässiga och Psykiska Symtom vid Demenssjukdom – BPSD. Information från läkemedelsverket (25–47). Läkemedelsverket: Stockholm, Sweden (in Swedish).Google Scholar
Nijk, R. M., Zuidema, S. U. and Koopmans, R. T. C. M. (2009). Prevalence and correlates of psychotropic drug use in Dutch nursing-home patients with dementia. International Psychogeriatrics, 21, 485–493. doi:10.1017/S1041610209008916.CrossRefGoogle ScholarPubMed
O’Connor, D. W., Ames, D., Gardner, B. and King, M. (2009). Psychosocial treatments of psychological symptoms in dementia: a systematic review of reports meeting quality standards. International Psychogeriatrics, 21, 241–251. doi:10.1017/S1041610208008223,CrossRefGoogle ScholarPubMed
Pollock, B. G.et al. (2002). Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. The American Journal of Psychiatry, 159, 460–465.CrossRefGoogle ScholarPubMed
Pollock, B. G.et al. (2007). A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. The American Journal of Geriatric Psychiatry, 15, 942–952.CrossRefGoogle ScholarPubMed
Ruths, S., Straand, J., Nygaard, H. A. and Aarsland, D. (2008). Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study – the Bergen District Nursing Home Study (BEDNURS). International Journal of Geriatric Psychiatry, 23, 889–895. doi:10.1002/gps.1998.CrossRefGoogle Scholar
Sandman, P. O., Adolfsson, R., Norberg, A., Nyström, L. and Winblad, B. (1988). Long-term care of the elderly. a descriptive study of 3600 institutionalized patients in the county of Västerbotten, Sweden. Comprehensive Gerontology. Section A, Clinical and Laboratory Sciences, 2, 120–132.Google ScholarPubMed
Schneider, L. S., Dagerman, K. S. and Insel, P. (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 294, 1934–1943. doi:10.1001/jama.294.15.1934.CrossRefGoogle ScholarPubMed
Schneider, L. S.et al. (2006). Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. The New England Journal of Medicine, 355, 1525–1538. doi:10.1056/NEJMoa061240.CrossRefGoogle ScholarPubMed
Selbaek, G., Kirkevold, Ø. and Engedal, K. (2008). The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes – a 12-month follow-up study. The American Journal of Geriatric Psychiatry, 16, 528–536.CrossRefGoogle ScholarPubMed
Statistics Sweden. (2010). Population Statistics. Örebro, Sweden: Statistics Sweden.Google Scholar
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S. and Gergel, I. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA, 291, 317–324. doi:10.1001/jama.291.3.317.CrossRefGoogle ScholarPubMed
Zuidema, S. U., de Jonghe, J. F. M., Verhey, F. R. J. and Koopmans, R. T. C. M. (2011). Psychotropic drug prescription in nursing home patients with dementia: influence of environmental correlates and staff distress on physicians’ prescription behavior. International Psychogeriatrics, 23, 1632–1639. doi:10.1017/S1041610211001438.CrossRefGoogle ScholarPubMed